Skip to content

Sinecatechins

DERMATOLOGICALS

Also known as: kunecatechins

FDA approvedATC D06BB12

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Sinecatechins is a drug catalogued in DrugCentral. It was first approved by the FDA in 2006. Recorded indications include Condyloma acuminatum and Perianal warts.

  • Indications: Condyloma acuminatum and Perianal warts.
  • ATC code: D06BB12 (Antivirals).
  • Molecular formula: C74H64O34; molecular weight 1497.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Condyloma acuminatum
  • Perianal warts

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2006-10-31FDA—MEDIGENE AG

ATC classification

ATC codeTherapeutic hierarchy
D06BB12DERMATOLOGICALS › ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE › CHEMOTHERAPEUTICS FOR TOPICAL USE › Antivirals

Chemical structure

Molecular formulaC74H64O34
Molecular weight1497.29 g/mol
CAS number84650-60-2
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sinecatechins used for?

DrugCentral lists the following indications for Sinecatechins: Condyloma acuminatum and Perianal warts.

When was Sinecatechins first approved?

Sinecatechins was first approved by the FDA in 2006.

What is the chemical formula of Sinecatechins?

Sinecatechins has the molecular formula C74H64O34 and a molecular weight of 1497.29 g/mol.

Browse: all drugs starting with S · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2006-10-31
AgencyFDA
Targets0
Indications2
FormulaC74H64O34
DrugCentral ID4785
Interactive profile